| Literature DB >> 30561316 |
Min Hyuk Choi, Myungsook Kim, Su Jin Jeong, Jun Yong Choi, In-Yong Lee, Tai-Soon Yong, Dongeun Yong, Seok Hoon Jeong, Kyungwon Lee.
Abstract
Elizabethkingia infections are difficult to treat because of intrinsic antimicrobial resistance, and their incidence has recently increased. We conducted a propensity score-matched case-control study during January 2016-June 2017 in South Korea and retrospectively studied data from patients who were culture positive for Elizabethkingia species during January 2009-June 2017. Furthermore, we conducted epidemiologic studies of the hospital environment and mosquitoes. The incidence of Elizabethkingia increased significantly, by 432.1%, for 2016-2017 over incidence for 2009-2015. Mechanical ventilation was associated with the acquisition of Elizabethkingia species. Because Elizabethkingia infection has a high case-fatality rate and is difficult to eliminate, intensive prevention of contamination is needed.Entities:
Keywords: Elizabethkingia anophelis; Elizabethkingia meningoseptica; Elizabethkingia miricola; South Korea; acquisition; antimicrobial resistance; bacteria; contamination source; mechanical ventilator
Mesh:
Year: 2019 PMID: 30561316 PMCID: PMC6302585 DOI: 10.3201/eid2501.171985
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Figure 1Rural areas of South Korea (Hwaseong-si, Gyeonggi-do; Paju-si, Gyeonggi-do; and Chungju-si, Chungbuk) where adult mosquitoes were collected during July–September 2017 and the urban location of the tertiary teaching hospital (Seodaemun-gu, Seoul) where the study of Elizabethkingia infection in patients was conducted during January 2009–June 2017.
Annual incidence and characteristics of Elizabethkingia acquisitions at a tertiary teaching hospital, Seoul, South Korea
| Characteristic | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 Jan–Jun |
|---|---|---|---|---|---|---|---|---|---|
| No. cases | 2 | 2 | 10 | 23 | 29 | 39 | 30 | 84 | 50 |
| Incidence | |||||||||
| Per 1 million inpatient-days | 2.93 | 2.98 | 14.60 | 33.14 | 42.43 | 55.74 | 40.66 | 109.82 | 127.79 |
| Per 1,000 inpatients | 0.02 | 0.02 | 0.10 | 0.23 | 0.30 | 0.39 | 0.28 | 0.75 | 0.88 |
| Sample type, no., may be multiple | |||||||||
| Respiratory | 2 | 0 | 2 | 14 | 25 | 27 | 26 | 76 | 48 |
| Blood culture | 0 | 2 | 2 | 2 | 2 | 3 | 1 | 4 | 3 |
| Urine culture | 0 | 0 | 5 | 2 | 2 | 3 | 1 | 1 | 0 |
| Other* | 0 | 0 | 1 | 5 | 1 | 7 | 2 | 6 | 1 |
| Species, no. | |||||||||
|
| 1 | 2 | 2 | 7 | 16 | 17 | 15 | 45 | 34 |
|
| 0 | 0 | 5 | 1 | 4 | 5 | 11 | 25 | 12 |
|
| 1 | 0 | 3 | 3 | 5 | 4 | 1 | 4 | 2 |
| Unconfirmed† | 0 | 0 | 0 | 12 | 4 | 13 | 3 | 10 | 2 |
*Includes 12 from body fluids, 4 wound swabs, 3 catheter tips, 2 oral swabs, 1 eye swab, and 1 ear swab. †Includes strains that were not stored for identification.
Figure 2Trends in the quarterly incidence of Elizabethkingia infection or colonization in a tertiary teaching hospital, Seoul, South Korea, January 2009–June 2017. Q1, January–March; Q2, April–June; Q3, July–September; Q4, October–December.
Baseline characteristics of patients in a tertiary teaching hospital who acquired Elizabethkingia and differences before and after 2016, Seoul, South Korea*
| Characteristic | Total, n = 269 | 2009–2015, n = 135 | 2016–June 2017, n = 134 | p value | |
|---|---|---|---|---|---|
| Median age, y (range) | 64.0 (47.0–74.0) | 65.0 (46.0–73.0) | 63.0 (47.0–74.0) | 0.67 | |
| Sex, no. (%) | 0.24 | ||||
| M | 165 (61.3) | 88 (65.2) | 77 (57.5) | ||
| F | 104 (38.7) | 47 (34.8) | 57 (42.5) |
| |
| Nosocomial infection, no. (%) | 254 (94.4) | 122 (90.4) | 132 (98.5) | 0.01 | |
| Median Charlson comorbidity index (range) | 5.0 (3.0–7.0) | 5.0 (3.0–7.0) | 5.0 (4.0–7.0) | 0.04 | |
| Comorbidities, no. (%)† | |||||
| Solid-organ tumor | 86 (32.0) | 46 (34.1) | 40 (29.9) | 0.54 | |
| Diabetes mellitus | 74 (27.5) | 28 (20.7) | 46 (34.3) | 0.02 | |
| Chronic pulmonary disease | 70 (26.0) | 18 (13.3) | 52 (38.8) | <0.01 | |
| Chronic kidney disease | 54 (20.1) | 22 (16.3) | 32 (23.9) | 0.16 | |
| Hemiplegia | 37 (13.8) | 14 (10.4) | 23 (17.2) | 0.15 | |
| Hematologic malignancy | 33 (12.3) | 15 (11.1) | 18 (13.4) | 0.69 | |
| Cerebrovascular disease | 31 (11.5) | 12 (8.9) | 19 (14.2) | 0.24 | |
| Dementia | 28 (10.4) | 12 (8.9) | 16 (11.9) | 0.54 | |
| Connective tissue disease | 23 (8.6) | 13 (9.6) | 10 (7.5) | 0.68 | |
| Mild liver disease | 13 (4.8) | 6 (4.4) | 7 (5.2) | 0.99 | |
| Clinical conditions | |||||
| Median hospitalization day of acquisition (range) | 33.0 (17.0–69 .0) | 28.0 (14.0–55.5) | 36.0 (18.0–75.0) | 0.02 | |
| Median length of hospitalization, d (range) | 69.0 (39.0–133.0) | 59.0 (35.0–99.5) | 78.0 (41.0–149.0) | 0.04 | |
| Mechanical ventilation, no. (%) | 214 (79.6) | 99 (73.3) | 115 (85.8) | 0.02 | |
| Steroid use, no. (%) | 161 (59.9) | 72 (53.3) | 89 (66.4) | 0.04 | |
| Prior ICU stay, no. (%) | 142 (52.8) | 73 (54.1) | 69 (51.5) | 0.76 | |
| Sample type, no. (%)† | |||||
| Respiratory | 219 (81.4) | 95 (70.4) | 124 (92.5) | <0.01 | |
| Blood culture | 19 (7.1) | 12 (8.9) | 7 (5.2) | 0.35 | |
| Urine culture | 14 (5.2) | 13 (9.6) | 1 (0.7) | <0.01 | |
| Other | 23 (8.6) | 16 (11.9) | 7 (5.2) | 0.08 | |
| Infection sign or symptom, no. (%) | |||||
| Pneumonia | 23 (8.6) | 9 (6.7) | 14 (10.4) | 0.37 | |
| Sepsis | 12 (4.5) | 7 (5.2) | 5 (3.7) | 0.78 | |
| Polymicrobial infection | 221 (82.2) | 110 (81.5) | 111 (82.8) | 0.90 | |
| Laboratory finding‡ | |||||
| Leukocyte count, 109 cells/L (range) | 8.2 (5.9–11.8) | 8.2 (6.2–12.5) | 7.8 (5.9–11.1) | 0.52 | |
| Hemoglobin concentration, g/dL (range) | 9.5 (8.4–10.5) | 9.8 (8.8–11.0) | 9.0 (8.1–10.2) | <0.01 | |
| Platelet count, 109/L (range) | 169.5 (82.0–268.0) | 161.0 (84.0–263.5) | 170.5 (80.0–271.0) | 0.48 | |
| Erythrocyte sedimentation rate, mm/h (range) | 49.0 (16.0–79.0) | 52.0 (14.0–85.0) | 39.5 (17.5–74.0) | 0.28 | |
| Total bilirubin, mg/dL (range) | 0.6 (0.3–1.4) | 0.7 (0.4–1.6) | 0.5 (0.3–1.2) | 0.04 | |
| Serum creatinine, ng/mL (range) | 0.6 (0.4–1.1) | 0.6 (0.4–1.1) | 0.6 (0.4–1.1) | 0.78 | |
| C-reactive protein, mg/L (range) | 51.4 (20.2–85.0) | 63.6 (30.7–93.9) | 35.2 (15.2–76.0) | <0.01 | |
| 14-d mortality, no. (%) | 32 (11.9) | 20 (14.8) | 12 (9.0) | 0.20 | |
| In-hospital mortality, no. (%) | 95 (35.3) | 56 (41.5) | 39 (29.1) | 0.05 | |
| Location, no. (%) | <0.01 | ||||
| Ward A | 27 (10.0) | 3 (2.2) | 24 (34.3) | ||
| Ward B | 39 (14.5) | 3 (2.2) | 36 (22.4) | ||
| ICU 1 | 19 (7.1) | 5 (3.7) | 14 (26.1) | ||
| ICU 2 | 3 (1.1) | 3 (2.2) | 0 | ||
| ICU 3 | 10 (3.7) | 6 (4.4) | 4 (3) | ||
| Emergency department | 8 (3) | 8 (5.9) | 0 | ||
| ICU 4 | 4 (1.5) | 2 (1.5) | 2 (1.5) | ||
| ICU 5 | 36 (13.4) | 21 (15.6) | 15 (11.2) | ||
| ICU 6 | 33 (12.3) | 20 (14.8) | 13 (9.7) | ||
| ICU 7 | 9 (3.3) | 5 (3.7) | 4 (3) | ||
| ICU 8 | 5 (1.9) | 4 (3) | 1 (0.7) | ||
| NICU 1 | 15 (5.6) | 7 (5.2) | 8 (6) | ||
| NICU 2 | 1 (0.4) | 0 | 1 (0.7) | ||
| Other | 60 (22.3) | 48 (35.6) | 12 (9.0) |
| |
| Antimicrobial drug exposure, no. (%) | |||||
| Penicillin§ | 26 (9.7) | 12 (8.9) | 14 (10.4) | 0.82 | |
| 1st-generation cephalosporin | 17 (6.3) | 8 (5.9) | 9 (6.7) | 0.99 | |
| 2nd-generation cephalosporin | 19 (7.1) | 10 (7.4) | 9 (6.7) | 0.99 | |
| 3rd-generation cephalosporin | 77 (28.6) | 42 (31.1) | 35 (26.1) | 0.44 | |
| 4th-generation cephalosporin | 37 (13.8) | 14 (10.4) | 23 (17.2) | 0.15 | |
| Aminoglycoside | 25 (9.3) | 12 (8.9) | 13 (9.7) | 0.98 | |
| Glycopeptide | 106 (39.4) | 52 (38.5) | 54 (40.3) | 0.86 | |
| Linezolid | 11 (4.1) | 8 (5.9) | 3 (2.2) | 0.22 | |
| Carbapenem | 57 (21.2) | 30 (22.2) | 27 (20.1) | 0.79 | |
| Tetracycline | 12 (4.5) | 6 (4.4) | 6 (4.5) | 0.99 | |
| Colistin | 7 2.6) | 7 (5.2) | 0 | 0.02 | |
| Trimethoprim–sulfamethoxazole | 32 (11.9) | 20 (14.8) | 12 (9.0) | 0.20 | |
| Lincosamide | 17 (6.3) | 8 (5.9) | 9 (6.7) | 0.99 | |
| Macrolide | 16 (5.9) | 10 (7.4) | 6 (4.5) | 0.45 | |
| Fluoroquinolone | 98 (36.4) | 45 (33.3) | 53 (39.6) | 0.35 | |
*ICU, intensive care unit; NICU, neonatal ICU. †May be multiple. ‡Reference ranges: leukocyte count, 4.0–10.8 × 109 cells/L; hemoglobin concentration, 13.0–17.4 g/dL for adult male and 11.7–16.0 g/dL for adult female; platelet count, 150–400 × 109/L; erythrocyte sedimentation rate, 0–15 mm/h for male and 0–20 mm/h for female; total bilirubin, 0.5–1.8 mg/dL for adult male, 0.4–1.5 mg/dL for adult female; serum creatinine, 0.68–1.19 ng/mL for adult male and 0.49–0.91 ng/mL for adult female; C-reactive protein, 0–8 mg/L. §Includes aminopenicillin, β-lactam/β-lactamase inhibitor.
Figure 3Pulsed-field gel electrophoresis dendrograms for 54 clinical isolates and 12 environmental isolates of Elizabethkingia species, Seoul, South Korea, 2017. E. anophelis (40 clinical isolates and 7 environmental isolates) showed 8 pulsotypes (A), E. miricola (10 clinical isolates and 3 environmental isolates) pulsotypes (B), and E. meningoseptica (4 clinical isolates and 2 environmental isolates) 2 pulsotypes (C). c, clinical; e, environmental; ICU, intensive care unit. Scale bar indicates percent relatedness.
Variables possibly associated with acquisition of Elizabethkingia species, before and after propensity score matching, in a tertiary teaching hospital, Seoul, South Korea
| Variable | Before matching |
| After matching | ||||
|---|---|---|---|---|---|---|---|
| Case-patients, n = 74 | Control-patients, n = 6,509 | p value | Case-patients, n = 52 | Control-patients, n = 156 | p value | ||
| Ward, no. (%) | <0.01 | 0.54 | |||||
| Ward A | 24 (32.4) | 587 (9.0) | 21 (40.4) | 76 (48.7) | |||
| Ward B | 36 (48.6) | 2,607 (40.1) | 25 (48.1) | 62 (39.7) | |||
| Intensive care unit 1 | 14 (18.9) | 3,315 (50.9) |
|
| 6 (11.5) | 18 (11.5) |
|
| Period of admission, no. (%) | 0.26 | 0.79 | |||||
| 2016 Jan–Mar | 14 (18.9) | 1,073 (16.5) | 6 (11.5) | 32 (20.5) | |||
| 2016 Apr–Jun | 14 (18.9) | 1,172 (18.0) | 10 (19.2) | 27 (17.3) | |||
| 2016 Jul–Sep | 11 (14.9) | 1,078 (16.6) | 11 (21.2) | 30 (19.2) | |||
| 2016 Oct–Dec | 16 (21.6) | 1,141 (17.5) | 6 (11.5) | 13 (8.3) | |||
| 2017 Jan–Mar | 15 (20.3) | 1,058 (16.3) | 10 (19.2) | 27 (17.3) | |||
| 2017 Apr–Jun | 4 (5.4) | 987 (15.2) |
|
| 9 (17.3) | 27 (17.3) |
|
| Median stay in 3 wards, d (range) | 55 (20–131) | 3 (2–8) | <0.01 | 32 (6–59) | 20 (5–49) | 0.27 | |
| Median age, y (range) | 66.5 (59.0–76.0) | 67.0 (57.0–75.0) | 0.72 |
| 63.5 (57.5–73.0) | 66.5 (54.0–77.0) | 0.79 |
| Sex, no. (%) | 0.44 | 0.63 | |||||
| M | 44 (59.5) | 4,197 (64.5) | 28 (53.8) | 76 (48.7) | |||
| F | 30 (40.5) | 2,312 (35.5) |
|
| 24 (46.2) | 80 (51.3) |
|
| Median Charlson comorbidity index (range) | 6 (4.0–7.0) | 5 (4.0–7.0) | 0.14 |
| 6 (4.0–6.5) | 6 (3.0–7.0) | 0.99 |
| Comorbidities, no. (%)* | |||||||
| Solid-organ tumor | 18 (24.3) | 1,766 (27.1) | 0.68 | 11 (21.2) | 53 (34.0) | 0.12 | |
| Diabetes mellitus | 11 (14.9) | 894 (13.7) | 0.91 | 7 (13.5) | 21 (13.5) | 0.99 | |
| Chronic pulmonary disease | 9 (12.2) | 207 (3.2) | <0.01 | 5 (9.6) | 9 (5.8) | 0.52 | |
| Chronic kidney disease | 11 (14.9) | 618 (9.5) | 0.17 | 8 (15.4) | 16 (10.3) | 0.45 | |
| Hematologic malignancy | 6 (8.1) | 164 (2.5) | 0.01 | 4 (7.7) | 9 (5.8) | 0.87 | |
| Dementia | 3 (4.1) | 147 (2.3) | 0.52 | 2 (3.8) | 8 (5.1) | 0.99 | |
| Connective tissue disease | 3 (4.1) | 253 (3.9) | 0.99 | 3 (5.8) | 9 (5.8) | 0.99 | |
| Mild liver disease | 2 (2.7) | 82 (1.3) | 0.56 | 1 (1.9) | 3 (1.9) | 0.99 | |
| Steroid use | 23 (31.1) | 562 (8.6) | <0.01 | 14 (26.9) | 34 (21.8) | 0.57 | |
| Mechanical ventilation | 72 (97.3) | 1,258 (19.3) | <0.01 |
| 50 (96.2) | 62 (39.7) | <0.01 |
| Antimicrobial exposure, no. (%) | |||||||
| Penicillin† | 5 (6.8) | 393 (6.0) | 0.99 | 2 (3.8) | 15 (9.6) | 0.31 | |
| 1st-generation cephalosporin | 2 (2.7) | 445 (6.8) | 0.24 | 1 (1.9) | 11 (7.1) | 0.30 | |
| 2nd-generation cephalosporin | 2 (2.7) | 184 (2.8) | 0.99 | 2 (3.8) | 2 (1.3) | 0.56 | |
| 3rd-generation cephalosporin | 26 (35.1) | 1,089 (16.7) | <0.01 | 15 (28.8) | 40 (25.6) | 0.79 | |
| 4th-generation cephalosporin | 0 | 1 | 0.99 | 0 | 0 | NA | |
| Aminoglycoside | 13 (17.6) | 118 (1.8) | <0.01 | 10 (19.2) | 12 (7.7) | 0.04 | |
| Glycopeptide | 40 (54.1) | 481 (7.4) | <0.01 | 27 (51.9) | 40 (25.6) | <0.01 | |
| Linezolid | 6 (8.1) | 40 (0.6) | <0.01 | 5 (9.6) | 5 (3.2) | 0.13 | |
| Carbapenem | 42 (56.8) | 416 (6.4) | <0.01 | 27 (51.9) | 42 (26.9) | <0.01 | |
| Tetracycline | 12 (16.2) | 58 (0.9) | <0.01 | 5 (9.6) | 7 (4.5) | 0.30 | |
| Trimethoprim–sulfamethoxazole | 17 (23.0) | 245 (3.8) | <0.01 | 11 (21.2) | 15 (9.6) | 0.05 | |
| Lincosamide | 7 (9.5) | 40 (0.6) | <0.01 | 2 (3.8) | 2 (1.3) | 0.56 | |
| Macrolide | 1 (1.4) | 286 (4.4) | 0.32 | 1 (1.9) | 4 (2.6) | 0.99 | |
| Fluoroquinolone | 43 (58.1) | 871 (13.4) | <0.01 | 30 (57.7) | 45 (28.8) | <0.01 | |
| Other | 5 (6.8) | 100 (1.5) | <0.01 | 4 (7.7) | 5 (3.2) | 0.33 | |
*May be multiple. †Includes aminopenicillin, β-lactam/β-lactamase inhibitor.
Results of univariate and multivariate analysis using conditional logistic regression of risk factors for the acquisition of Elizabethkingia species at a tertiary teaching hospital after propensity score matching, Seoul, South Korea*
| Variable | Univariate analysis | Multivariate analysis† | |||
|---|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | ||
| Ward | |||||
| Ward A | Reference | ||||
| Ward B | 0.87 (0.41–1.79) | 0.70 | |||
| Intensive care unit 1 | 0.69 (0.18–2.22) | 0.56 |
|
|
|
| Period of admission | |||||
| 2016 Jan–Mar | Reference | ||||
| 2016 Apr–Jun | 8.03 (0.79–81.98) | 0.08 | |||
| 2016 Jul–Sep | 8.87 (0.74–105.84) | 0.08 | |||
| 2016 Oct–Dec | 10.62 (0.64–176.77) | 0.10 | |||
| 2017 Jan–Mar | 8.87 (0.97–81.16) | 0.05 | |||
| 2017 Apr–Jun | 8.34 (0.71–98.76) | 0.09 |
|
|
|
| Median stay in 3 wards, d | 1.01 (0.99–1.02) | 0.25 | |||
| Age, y | 1.00 (0.98–1.02) | 0.87 | |||
| Male sex | 1.06 (0.55–2.02) | 0.87 | |||
| Charlson comorbidity index | 0.97 (0.85–1.12) | 0.69 |
|
|
|
| Comorbidities‡ | |||||
| Solid organ tumor | 0.48 (0.21–1.08) | 0.08 | |||
| Diabetes mellitus | 0.89 (0.34–2.31) | 0.81 | |||
| Chronic pulmonary disease | 1.85 (0.55–6.28) | 0.32 | |||
| Chronic kidney disease | 1.52 (0.60–3.85) | 0.38 | |||
| Hematologic malignancy | 1.00 (0.25–4.00) | 0.99 | |||
| Dementia | 0.57 (0.12–2.77) | 0.49 | |||
| Connective tissue disease | 0.80 (0.21–3.05) | 0.75 | |||
| Mild liver disease | 1.00 (0.10–9.61) | 0.99 | |||
| Steroid use | 1.55 (0.62–3.89) | 0.35 | |||
| Mechanical ventilation | 64.54 (8.76–475.30) | <0.01 |
| 50.44 (6.74–377.48) | <0.01 |
| Antimicrobial exposure | |||||
| Penicillin§ | 0.32 (0.07–1.54) | 0.16 | |||
| 1st-generation cephalosporin | 0.29 (0.03–2.88) | 0.29 | |||
| 2nd-generation cephalosporin | 3.00 (0.42–21.30) | 0.27 | |||
| 3rd-generation cephalosporin | 0.97 (0.46–2.01) | 0.93 | |||
| 4th-generation cephalosporin | NA | ||||
| Aminoglycoside | 3.18 (1.21–8.31) | 0.02 | 2.30 (0.62–8.47) | 0.21 | |
| Glycopeptide | 3.96 (1.82–8.63) | <0.01 | 1.72 (0.50–5.86) | 0.39 | |
| Linezolid | 8.84 (0.97–80.69) | 0.05 | |||
| Carbapenem | 4.16 (1.99–8.72) | <0.01 | 1.63 (0.55–4.85) | 0.38 | |
| Tetracycline | 1.65 (0.42–6.43) | 0.47 | |||
| Trimethoprim/sulfamethoxazole | 2.11 (0.90–4.91) | 0.09 | |||
| Lincosamide | 6.00 (0.54–66.17) | 0.14 | |||
| Macrolide | 0.75 (0.08–6.71) | 0.80 | |||
| Fluoroquinolone | 3.42 (1.70–6.87) | <0.01 | 2.01 (0.71–5.69) | 0.19 | |
| Other | 2.09 (0.48–9.03) | 0.33 | |||
*OR, odds ratio; NA, not available. †Only variables with p<0.05 in the univariate model were included in the multivariate model. ‡May be multiple. §Includes aminopenicillin, β-lactam/β-lactamase inhibitor.
Results of univariable and multivariable analyses of risk factors for in-hospital mortality of patients with a true pathogen of Elizabethkingia in a tertiary teaching hospital, Seoul, South Korea
| In-hospital mortality | Total, n = 30 | Survived, n = 20 | Died, n = 10 | p value |
| Median age, y (range) | 68.5 (61.0–80.0) | 69.5 (60.5–79.5) | 66.5 (63.0–80.0) | 0.86 |
| Male sex, no. (%) | 19 (63.3) | 11 (55.0) | 8 (80.0) | 0.35 |
| Patients from the 3 study wards, no. (%) | 7 (23.3) | 5 (25.0) | 2 (20.0) | 0.99 |
| Nosocomial infection, no. (%) | 29 (96.7) | 19 (95.0) | 10 (100.0) | 0.99 |
| Median Charlson comorbidity index (range) | 6 (5.0–9.0) | 6 (4.5–7.5) | 6 (5.0–9.0) | 0.93 |
| Clinical condition | ||||
| Median hospitalization day of acquisition (range) | 26.5 (13.0–58.0) | 20.5 (12.0–32.0) | 52.5 (26.0–81.0) | 0.03 |
| Median length of hospitalization, d (range) | 47.5 (29.0–89.0) | 38.5 (27.5–67.5) | 77.5 (54.0–210.0) | 0.04 |
| Mechanical ventilation, no. (%) | 24 (80.0) | 15 (75.0) | 9 (90.0) | 0.63 |
| Steroid use, no. (%) | 14 (46.7) | 9 (45.0) | 5 (50.0) | 0.99 |
| Antimicrobial treatment, no. (%) | ||||
| Penicillin* | 5 (16.7) | 3 (15.0) | 2 (20.0) | 0.99 |
| 1st-generation cephalosporin | 3 (10) | 2 (10.0) | 1 (10.0) | 0.99 |
| 2nd-generation cephalosporin | 5 (16.7) | 4 (20.0) | 1 (10.0) | 0.86 |
| 3rd-generation cephalosporin | 8 (26.7) | 4 (20.0) | 4 (40.0) | 0.47 |
| 4th-generation cephalosporin | 7 (23.3) | 4 (20.0) | 3 (30.0) | 0.88 |
| Aminoglycoside | 1 (3.3) | 1 (5.0) | 0 | 0.99 |
| Glycopeptide | 13 (43.3) | 6 (30.0) | 7 (70.0) | 0.09 |
| Linezolid | 4 (13.3) | 2 (10.0) | 2 (20.0) | 0.85 |
| Carbapenem | 7 (23.3) | 2 (10.0) | 5 (50.0) | 0.05 |
| Tetracycline | 8 (26.7) | 7 (35.0) | 1 (10.0) | 0.30 |
| Colistin | 3 (10) | 0 | 3 (30.0) | 0.05 |
| Trimethoprim/sulfamethoxazole | 7 (23.3) | 2 (10.0) | 5 (50.0) | 0.05 |
| Lincosamide | 5 (16.7) | 1 (5.0) | 4 (40.0) | 0.06 |
| Macrolide | 1 (3.3) | 0 | 1 (10.0) | 0.72 |
| Fluoroquinolone | 9 (30) | 4 (20.0) | 5 (50.0) | 0.21 |
| Other | 5 (16.7) | 2 (10.0) | 3 (30.0) | 0.39 |
*Includes aminopenicillin, β-lactam/β-lactamase inhibitor.